Robotic-assisted clinical outcomes again proven to provide economic benefits across healthcare system.

Invivo Robotics (ISIN: CN2347660099), one of the pioneers in the rapidly emerging field of robotic-assisted minimally invasive surgery, is pleased to announce the published results of a new study “A Multidimensional Analysis of Prostate Surgery Costs: Robotic-Assisted versus Retropubic Radical Prostatectomy.”

Prostate cancer is the most commonly..

View more at https://www.1888pressrelease.com/invivo-robotics-study-results-cost-savings-associated-with-pr-639994.html